Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.52 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | PAM | P19021 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27569028 | 1.00 | CYP1A2 (0.64) | CYP1A2DGKAMGAMGAASI | |
| SCHEMBL127083 | 0.97 | — | — | |
| Fluoride SCHEMBL27898416 | 0.95 | CYP1A2 (0.64) | CYP1A2DGKAMGAMGAASI | |
| SCHEMBL27760457 | 0.95 | CYP1A2 (0.64) | CYP1A2DGKAMGAMGAASI | |
| Ammonia Solution, Strong SCHEMBL27681724 | 0.95 | CYP1A2 (0.64) | CYP1A2DGKAMGAMGAASI | |
| SCHEMBL28212348 | 0.95 | CYP1A2 (0.64) | CYP1A2DGKAMGAMGAASI | |
| Water SCHEMBL28265567 | 0.95 | CYP1A2 (0.64) | CYP1A2DGKAMGAMGAASI | |
| Hydrochloric Acid SCHEMBL3636571 | 0.93 | DGKA (0.68) | CYP1A2DGKAMGAMGAASI | |
| Hydrochloric Acid SCHEMBL7018660 | 0.93 | DGKA (0.68) | CYP1A2DGKAMGAMGAASI | |
| SCHEMBL11045667 | 0.93 | CYP1A2 (0.61) | CYP1A2DGKAMGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| CN-109195963-A | 6-hydroxy-4-oxo-1, 4-dihydropyrimidine-5-carboxamides as APJ agonists | 百时美施贵宝公司 | 2019-01-11 | — | — | CN | disclosed |
| CN-104306974-B | The method of the ephrosis for the treatment of contrast agent induction | 诺华股份有限公司 | 2017-06-13 | — | — | CN | disclosed |
| CN-101720319-A | Thiazolidine derivatives and methods for the preparation thereof | KAINOS MEDICINE INC | 2010-06-02 | — | — | CN | disclosed |
| CN-1596253-A | Spiro-hydantoin compounds useful as anti-inflammatory agents | BRISTOL MYERS SQUIBB CO (US) | 2005-03-16 | — | — | CN | disclosed |
| CN-1437587-A | Benzoxazepinones and their use as squalene synthetase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-08-20 | — | — | CN | disclosed |
| CN-1118467-C | 1,3,8-triaza-spiro [4,5] decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2003-08-20 | — | — | CN | disclosed |
| CN-1222521-A | 1,3,8-triaza-spiro [4,5] decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 1999-07-14 | — | — | CN | disclosed |
| CN-1043647-C | Novel peptide compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-06-16 | — | — | CN | disclosed |
| CN-1182419-A | Novel pyridine derivatives and medicine containing the same as active ingredient | SS PHARMACEUTICAL CO (JP) | 1998-05-20 | — | — | CN | disclosed |
| CN-1120047-A | New peptide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-04-10 | — | — | CN | disclosed |
| CN-1030607-C | Tetracyclic compounds having anti-allergic and anti-asthmatic activities, their prepn. and use | SANKYO CO (JP) | 1996-01-03 | — | — | CN | disclosed |
| CN-1066660-A | Peptide compounds and process for preparing same | FUJISAWA PHARMACEUTICAL CO (JP) | 1992-12-02 | — | — | CN | disclosed |
| CN-1051360-A | Have agaist allergic symptoms and the active new tetracyclic compound of anti-asthma, its preparation and application | SANKYO CO (JP) | 1991-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | GAA 2026/4885PTGS2 4805/4885PDE4D 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.